Mira Pharmaceuticals, Inc. announced on October 23, 2025, that it has started a Phase 1 clinical trial for its drug Ketamir-2, aimed at treating chemotherapy-induced peripheral neuropathy, a condition with no approved therapies. The trial showed no serious safety concerns, and Ketamir-2 demonstrated promising results compared to existing drugs like gabapentin.